Leaflet ORFIRIL LONG 300mg prolonged release capsules
Indicated for: epilepsy; bipolar disorder
Route of administration: oral
Substance: valproic acid + salts (antiepileptics)
ATC: N03AG01 (Nervous system | Antiepileptics | Fatty acid derivatives)
This medicine may affect your ability to drive or use machines.
Dose adjustment may be needed in liver disease.
Dose adjustment may be needed in kidney disease.
This medicine may cause dizziness or vertigo.
Effective contraception is required during treatment.
Do not use this medicine during pregnancy.
Periodic laboratory tests may be required during treatment.
Seek medical help if suicidal thoughts or major behavior changes occur.
This medicine may affect fetal development.
This medicine may cause drowsiness or reduced alertness.
Valproic acid and its salts (e.g., sodium valproate) are used to treat epilepsy, bipolar disorder, and prevent migraines. They stabilize brain electrical activity, preventing seizures and episodes of mania or depression.
Valproic acid increases GABA (gamma-aminobutyric acid) levels, an inhibitory neurotransmitter, reducing neuronal excitability. It is indicated for generalized and focal epilepsy, bipolar disorder, and migraine prevention.
Side effects may include nausea, drowsiness, weight gain, or tremor. Rarely, it can affect the liver or pancreas. It is contraindicated during pregnancy due to the risk of congenital malformations. Treatment must be monitored by a doctor.
General data about ORFIRIL LONG 300mg
- Substance: valproic acid + salts
- Date of last drug list: 01-07-2015
- Commercial code: W08722001
- Concentration: 300mg
- Pharmaceutical form: prolonged release capsules
- Quantity: 50
- Product type: generic
- Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.
Pharmaceutical forms available for valproic acid + salts
- capsules with prolonged-release mini-tablets
- prolonged release capsules
- gastro-resistant soft capsules
- prolonged-release tablets
- film-coated tablets
- modified-release film-coated tablets
- gastro-resistant film-coated tablets
- gastro-resistant tablets
- prolonged-release granules
- lyophilizate+solvent for solution
- syrup
Concentrations available for valproic acid + salts
- 1000mg
- 100mg
- 150mg
- 200mg
- 200mg/5ml
- 250mg
- 300mg
- 300mg/5ml
- 400mg/4ml
- 500mg
- 50mg/ml
- 57.64mg/ml
- 600mg
- 750mg